Patents

Literature

Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.

37 results about "HIF prolyl-hydroxylase inhibitor" patented technology

Filter

Efficacy Topic

Property

Owner

Technical Advancement

Application Domain

Technology Topic

Technology Field Word

Patent Country/Region

Patent Type

Patent Status

Application Year

Inventor

Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors (HIF-PHIs) also known as Hypoxia-Inducible Factor stabilizers (HIF stabilizers) are members of a class of new drugs that act by inhibiting prolyl hydroxylase which is responsible to break down the hypoxia-inducible factor (HIF) under normoxic conditions.

Substituted 4-Hydroxypyrimidine-5-Carboxamides

ActiveUS20090239876A1Increase productionReduce productionBiocideOrganic chemistryProlyl HydroxylasesHif prolyl hydroxylase

The present invention relates to substituted 4-hydroxypyrimidine-5-carboxamides useful as HIF prolyl hydroxylase inhibitors to treat anemia and like conditions.

Substituted 4-Hydroxypyrimidine-5-Carboxamides

Substituted 4-Hydroxypyrimidine-5-Carboxamides

Substituted 4-Hydroxypyrimidine-5-Carboxamides

Owner:MERCK SHARP & DOHME LLC

Isoquinolone compound and application thereof

InactiveCN108341777AOrganic chemistryBlood disorderDiseaseIschemia

The invention relates to an isoquinolone compound and application thereof. The invention in particular relates to an isoquinolone compound used as a HIF prolyl hydroxylase inhibitor (HIF-PHI) and a pharmaceutical composition thereof. Moreover, the present invention provides the application of the isoquinolinone compound or the pharmaceutical composition thereof in the preparation of a medicament for preventing or treating HIF-associated or HIF-mediated diseases as anemia or ischemia, local ischemia or hypoxia.

Isoquinolone compound and application thereof

Isoquinolone compound and application thereof

Isoquinolone compound and application thereof

Owner:SICHUAN KELUN BIOTECH BIOPHARMACEUTICAL CO LTD

Compositions and methods for treating anemia

PendingUS20160143891A1Raise serum hemoglobinRiskHeavy metal active ingredientsBiocideDosing regimenNephrosis

Provided herein are specific doses of, and dosing regimens for, using a HIF prolyl hydroxylase inhibitor in treating or preventing anemia, such as anemia secondary to or associated with chronic kidney disease, anemia associated with or resulting from chemotherapy, or anemia associated with AIDS.

Compositions and methods for treating anemia

Compositions and methods for treating anemia

Compositions and methods for treating anemia

Owner:AKEBIA THERAPEUTICS

Compositions and Methods for Treating Anemia

ActiveUS20180092892A1Reduced average total daily doseOrganic chemistryAmide active ingredientsRegimenNon dialysis dependent

Provided herein are specific doses of, and dosing regimens for, using a HIF prolyl hydroxylase inhibitor in treating or preventing anemia, such as anemia secondary to or associated with chronic kidney disease, anemia secondary to or associated with non-dialysis dependent chronic kidney disease anemia associated with or resulting from chemotherapy, or anemia associated with AIDS.

Compositions and Methods for Treating Anemia

Compositions and Methods for Treating Anemia

Compositions and Methods for Treating Anemia

Owner:AKEBIA THERAPEUTICS

Spiroindalones

ActiveUS20100137297A1Increase productionReduce productionBiocideOrganic chemistryHif prolyl hydroxylaseProlyl Hydroxylases

The present invention relates to spiroindalone compounds useful as HIF prolyl hydroxylase inhibitors to treat anemia and like conditions.

Spiroindalones

Spiroindalones

Spiroindalones

Owner:MERCK SHARP & DOHME LLC

Spiroazaindoles

ActiveUS20110152304A1Increased endogenous productionReduced endogenous productionBiocideOrganic chemistryProlyl HydroxylasesHif prolyl hydroxylase

The present invention relates to spiroazaindole compounds useful as HIF prolyl hydroxylase inhibitors to treat anemia and like conditions.

Spiroazaindoles

Spiroazaindoles

Spiroazaindoles

Owner:MERCK SHARP & DOHME LLC

Novel 1,8-naphthyridine compounds

InactiveCN101663037AOrganic active ingredientsOrganic chemistryBiochemistryProlyl Hydroxylases

The present invention relates to naphthyridine compounds useful as HIF prolyl hydroxylase inhibitors to treat anemia and like conditions.

Novel 1,8-naphthyridine compounds

Novel 1,8-naphthyridine compounds

Novel 1,8-naphthyridine compounds

Owner:MERCK & CO INC

Novel 1.8-naphthyridine compounds

InactiveUS20100056563A1Increased endogenous productionReduced endogenous productionBiocideOrganic chemistryProlyl HydroxylasesHif prolyl hydroxylase

The present invention relates to naphthyridine compounds useful as HIF prolyl hydroxylase inhibitors to treat anemia and like conditions.

Novel 1.8-naphthyridine compounds

Novel 1.8-naphthyridine compounds

Novel 1.8-naphthyridine compounds

Owner:MERCK SHARP & DOHME CORP

Tetrahydrofuropyridones

ActiveUS20100331358A1BiocideOrganic chemistryProlyl HydroxylasesHif prolyl hydroxylase

The present invention relates to Tetrahydrofuropyridones compounds useful as HIF prolyl hydroxylase inhibitors to treat anemia and like conditions.

Tetrahydrofuropyridones

Tetrahydrofuropyridones

Tetrahydrofuropyridones

Owner:MERCK SHARP & DOHME LLC

Substituted pyrimidines

ActiveUS20130018053A1BiocideOrganic chemistryCombinatorial chemistryHif prolyl hydroxylase

The present invention relates to substituted pyrimidines useful as HIF prolyl hydroxylase inhibitors to treat anemia and like conditions.

Substituted pyrimidines

Substituted pyrimidines

Substituted pyrimidines

Owner:BIODURO BAONUO TECH BEIJING CO LTD +1

Substituted pyrimidines

ActiveUS20140235583A1BiocideOrganic active ingredientsCombinatorial chemistryProlyl Hydroxylases

The present invention relates to substituted pyrimidines useful as HIF prolyl hydroxylase inhibitors to treat anemia and like conditions.

Substituted pyrimidines

Substituted pyrimidines

Substituted pyrimidines

Owner:MERCK SHARP & DOHME LLC +2

Tetrahydro-1H-pyrrolo fused pyridones

ActiveUS8372863B2Increase productionReduce productionBiocideOrganic chemistryHif prolyl hydroxylasePyrrole

The present invention relates to tetrahydro-1H-pyrrolo fused pyridone compounds useful as HIF prolyl hydroxylase inhibitors to treat anemia and like conditions.

Tetrahydro-1H-pyrrolo fused pyridones

Tetrahydro-1H-pyrrolo fused pyridones

Tetrahydro-1H-pyrrolo fused pyridones

Owner:MERCK SHARP & DOHME LLC

Spiroazaindoles

ActiveUS8492398B2BiocideOrganic chemistryBiochemistryProlyl Hydroxylases

The present invention relates to spiroazaindole compounds useful as HIF prolyl hydroxylase inhibitors to treat anemia and like conditions.

Spiroazaindoles

Spiroazaindoles

Spiroazaindoles

Owner:MERCK SHARP & DOHME LLC

Tetrahydrofuropyridones

ActiveUS8471024B2BiocideOrganic chemistryProlyl HydroxylasesHif prolyl hydroxylase

The present invention relates to Tetrahydrofuropyridones compounds useful as HIF prolyl hydroxylase inhibitors to treat anemia and like conditions.

Tetrahydrofuropyridones

Tetrahydrofuropyridones

Tetrahydrofuropyridones

Owner:MERCK SHARP & DOHME LLC

Tetrahydro-1h-pyrrolo fused pyridones

ActiveUS20110009406A1Increased endogenous productionReduced endogenous productionBiocideOrganic chemistryProlyl HydroxylasesStereochemistry

The present invention relates to tetrahydro-1H-pyrrolo fused pyridone compounds useful as HIF prolyl hydroxylase inhibitors to treat anemia and like conditions.

Tetrahydro-1h-pyrrolo fused pyridones

Tetrahydro-1h-pyrrolo fused pyridones

Tetrahydro-1h-pyrrolo fused pyridones

Owner:MERCK SHARP & DOHME LLC

Compositions and methods for treating anemia

InactiveCN105451739AImprove the level ofHeavy metal active ingredientsBiocideRegimenEnzyme inhibitor

Provided herein are specific doses of, and dosing regimens for, using an HIF prolyl hydroxylase inhibitor in treating or preventing anemia, such as anemia secondary to or associated with chronic kidney disease, anemia associated with or resulting from chemotherapy, or anemia associated with AIDS.

Compositions and methods for treating anemia

Compositions and methods for treating anemia

Compositions and methods for treating anemia

Owner:AKEBIA THERAPEUTICS

Tetrahydrothieno pyridines

ActiveUS20110009425A1Increased endogenous productionReduced endogenous productionBiocideNervous disorderPyridineHif prolyl hydroxylase

The present invention relates to tetrahydrothienopyridine compounds useful as HIF prolyl hydroxylase inhibitors to treat anemia and like conditions.

Tetrahydrothieno pyridines

Tetrahydrothieno pyridines

Tetrahydrothieno pyridines

Owner:MERCK SHARP & DOHME LLC

Substituted 4-hydroxypyrimidine-5-carboxamides

ActiveUS8278304B2Increase productionReduce productionBiocideOrganic chemistryProlyl HydroxylasesHif prolyl hydroxylase

The present invention relates to substituted 4-hydroxypyrimidine-5-carboxamides useful as HIF prolyl hydroxylase inhibitors to treat anemia and like conditions.

Substituted 4-hydroxypyrimidine-5-carboxamides

Substituted 4-hydroxypyrimidine-5-carboxamides

Substituted 4-hydroxypyrimidine-5-carboxamides

Owner:MERCK SHARP & DOHME LLC

Tetrahydro-1H-pyrrolo fused pyridones

InactiveCN101951776AReduce anemiaBiocideOrganic active ingredientsDiseaseProlyl Hydroxylases

The present invention relates to tetrahydro-1H-pyrrolo fused pyridone compounds useful as HIF prolyl hydroxylase inhibitors to treat anemia and like conditions.

Tetrahydro-1H-pyrrolo fused pyridones

Tetrahydro-1H-pyrrolo fused pyridones

Tetrahydro-1H-pyrrolo fused pyridones

Owner:SCHERING AG

Substituted pyrimidines

ActiveUS9034851B2BiocideOrganic active ingredientsCombinatorial chemistryHif prolyl hydroxylase

The present invention relates to substituted pyrimidines useful as HIF prolyl hydroxylase inhibitors to treat anemia and like conditions.

Substituted pyrimidines

Substituted pyrimidines

Substituted pyrimidines

Owner:MERCK SHARP & DOHME LLC +2

Substituted 4-hydroxypyrimidine-5-carboxamides

ActiveUS20120108600A1Increase productionReduce productionOrganic chemistryBlood disorderProlyl HydroxylasesHif prolyl hydroxylase

The present invention relates to substituted 4-hydroxypyrimidine-5-carboxamides useful as HIF prolyl hydroxylase inhibitors to treat anemia and like conditions.

Substituted 4-hydroxypyrimidine-5-carboxamides

Substituted 4-hydroxypyrimidine-5-carboxamides

Substituted 4-hydroxypyrimidine-5-carboxamides

Owner:MERCK SHARP & DOHME LLC

Tetrahydrothieno pyridines

ActiveUS8445680B2Increase productionReduce productionBiocideNervous disorderHif prolyl hydroxylaseProlyl Hydroxylases

The present invention relates to tetrahydrothienopyridine compounds useful as HIF prolyl hydroxylase inhibitors to treat anemia and like conditions.

Tetrahydrothieno pyridines

Tetrahydrothieno pyridines

Tetrahydrothieno pyridines

Owner:MERCK SHARP & DOHME LLC

Inhibitors of hif prolyl hydroxylase

ActiveUS20170240555A1Organic chemistryBlood disorderDrug carrierProlyl Hydroxylases

The present invention concerns a compound of formula I or a pharmaceutically acceptable salt thereof, which inhibit HIF prolyl hydroxylase, their use for enhancing endogenous production of erythropoietin, and for treating conditions associated with reduced endogenous production of erythropoietin such as anemia and like conditions, as well as pharmaceutical compositions comprising such a compound and a pharmaceutical carrier.

Inhibitors of hif prolyl hydroxylase

Inhibitors of hif prolyl hydroxylase

Inhibitors of hif prolyl hydroxylase

Owner:MERCK SHARP & DOHME LLC +1

Substituted pyrimidines

ActiveUS9006433B2BiocideOrganic chemistryCombinatorial chemistryHif prolyl hydroxylase

The present invention relates to substituted pyrimidines useful as HIF prolyl hydroxylase inhibitors to treat anemia and like conditions.

Substituted pyrimidines

Substituted pyrimidines

Substituted pyrimidines

Owner:BIODURO BAONUO TECH BEIJING CO LTD +1

Substituted-1,3,8-triazaspiro[4.5]decane-2,4-diones

ActiveUS8921555B2Increase productionReduce productionBiocideOrganic chemistryCombinatorial chemistryHif prolyl hydroxylase

The present invention relates to substituted 1,3,8-triazaspiro[4.5]decame-2,4-diones useful as HIF prolyl hydroxylase inhibitors to treat anemia and like conditions.

Substituted-1,3,8-triazaspiro[4.5]decane-2,4-diones

Substituted-1,3,8-triazaspiro[4.5]decane-2,4-diones

Substituted-1,3,8-triazaspiro[4.5]decane-2,4-diones

Owner:MERCK SHARP & DOHME LLC

Inhibitors of hif prolyl hydroxylase

InactiveUS20170226120A1Organic chemistryBlood disorderHif prolyl hydroxylaseProlyl Hydroxylases

The present invention concerns compounds of formula I or pharmaceutically acceptable salts thereof, which inhibit HIF prolyl hydroxylase, their use for enhancing endogenous production of erythropoietin, and for treating conditions associated with reduced endogenous production of erythropoietin such as anemia and like conditions, as well as pharmaceutical compositions comprising such a compound and a pharmaceutical carrier.

Inhibitors of hif prolyl hydroxylase

Inhibitors of hif prolyl hydroxylase

Inhibitors of hif prolyl hydroxylase

Owner:MSD R&D (CHINA) CO LTD +1

Substituted 4-hydroxypyrimidine-5-carboxamides

ActiveUS8815865B2Increase productionReduce productionOrganic chemistryBlood disorderProlyl HydroxylasesHif prolyl hydroxylase

The present invention relates to substituted 4-hydroxypyrimidine-5-carboxamides useful as HIF prolyl hydroxylase inhibitors to treat anemia and like conditions.

Substituted 4-hydroxypyrimidine-5-carboxamides

Substituted 4-hydroxypyrimidine-5-carboxamides

Substituted 4-hydroxypyrimidine-5-carboxamides

Owner:MERCK SHARP & DOHME LLC

Co-crystal of an orally available HIF prolyl hydroxylase inhibitor

ActiveUS11192860B2Improve propertiesEfficient releaseOrganic chemistry methodsInorganic non-active ingredientsDiseaseEnzyme Inhibitor Agent

The present invention relates to a co-crystal of roxadustat with L-proline and to a process for its preparation. Furthermore, the invention relates to a pharmaceutical composition comprising said roxadustat L-proline co-crystal, at least one pharmaceutically acceptable excipient and optionally at least one photostabilizing agent. The pharmaceutical composition of the present invention can be used as a medicament, in particular for the treatment and / or prevention of anemia in patients with end-stage renal disease (ESRD) and / or chronic kidney disease (CKD).

Co-crystal of an orally available HIF prolyl hydroxylase inhibitor

Co-crystal of an orally available HIF prolyl hydroxylase inhibitor

Co-crystal of an orally available HIF prolyl hydroxylase inhibitor

Owner:SANDOZ AG

Substituted pyrimidines

ActiveUS9079930B2Organic active ingredientsGroup 5/15 element organic compoundsCombinatorial chemistryHif prolyl hydroxylase

The present invention relates to substituted pyrimidines useful as HIF prolyl hydroxylase inhibitors to treat anemia and like conditions.

Substituted pyrimidines

Substituted pyrimidines

Substituted pyrimidines

Owner:BIODURO BAONUO TECH BEIJING CO LTD +2

Spiroindalones

ActiveUS8309544B2Increase productionReduce productionBiocideOrganic chemistryProlyl HydroxylasesHif prolyl hydroxylase

The present invention relates to spiroindalone compounds useful as HIF prolyl hydroxylase inhibitors to treat anemia and like conditions.

Spiroindalones

Spiroindalones

Spiroindalones

Owner:MERCK SHARP & DOHME LLC

Popular searches

Anemia Methylamide HIF prolyl-hydroxylase inhibitor Carboxamide Disease injury Drug Isoquinoline Quinoline Pharmaceutical drug Pharmacology

Who we serve

R&D Engineer
R&D Manager
IP Professional

Why Eureka

Industry Leading Data Capabilities
Powerful AI technology
Patent DNA Extraction

Social media

Try Eureka

PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap